Search for: "Celgene Corporation" Results 1 - 20 of 48
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Jul 2014, 6:43 am by Pete Strom
Qui-Tam Lawsuit Against Celgene for Off-Label Marketing of Drugs Will Proceed A qui-tam lawsuit brought against Celgene Corporation for two of its cancer drugs will proceed, according to a judge that refused to throw the lawsuit out. [read post]
30 Jun 2010, 3:36 am by By DEALBOOK
Celgene Corporation, the biopharmaceutical company, said Wednesday that it would buy Abraxis BioScience in a cash and stock deal that values the company at $2.9 billion. [read post]
21 Apr 2014, 5:52 am
("Andrulis") filed a patent infringement action against Celgene Corporation ("Celgene") alleging direct, induced, and contributory infringement. [read post]
27 Jul 2017, 5:28 am by Greene LLP
Celgene Corporation, a pharmaceuticals manufacturer headquartered in Summit, New Jersey will pay $280 million to settle fraud allegations related to the “off-label” promotion of two cancer treatment drugs for uses not approved by the Food and Drug Administration (“FDA”). [read post]
27 Jul 2017, 5:28 am by Greene LLP
Celgene Corporation, a pharmaceuticals manufacturer headquartered in Summit, New Jersey will pay $280 million to settle fraud allegations related to the “off-label” promotion of two cancer treatment drugs for uses not approved by the Food and Drug Administration (“FDA”). [read post]
30 Jun 2012, 9:56 pm by Mark Summerfield
Celgene Corporation [2012] APO 71 (25 June 2012) Manner of Manufacture – whether a system for dispensing a drug which provides a ‘prescription approval’ is patent-eligible Back in January, we reported a decision of the Australian Patent Office in which patent claims from Celgene corporation, relating to a method of dispensing drugs with significant safety issues (such as thalidomide), were rejected as being directed to an unpatentable… [read post]
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
30 Jun 2012, 11:02 pm by Mark Summerfield
We recently reported the Australian Patent Office decision in Celgene Corporation [2012] APO 71, relating to a system for dispensing drugs with significant safety issues (such as thalidomide). [read post]
21 Jun 2010, 7:29 am by Theo Francis
Image source: mijita via Flickr ———— Want to see more of what’s hidden in corporate filings? [read post]
19 May 2012, 10:25 am
The plaintiff, David Schmidt, alleged retaliation after he blew the whistle against his employer, Celgene Corporation, and CVS/Caremark Corporation, one of Celgene’s distributors. [read post]
25 Jan 2012, 10:01 pm by Mark Summerfield
Celgene Corporation [2012] APO 12 (17 January 2012) Manner of Manufacture – whether a method of dispensing a drug with a ‘prescription approval’ step is patent-eligible – novelty – whether use of a ‘prescription approval code’ makes method new We wrote back in June last year about Celgene Corporation’s unsuccessful application for an extension of term of a patent for the drug REVLIMID the active ingredient of which… [read post]
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
10 Apr 2017, 5:00 am by John Jascob
By Jacquelyn LumbThe Division of Corporation Finance advised Celgene Corporation that it was unable to concur with the company’s view that it could omit a shareholder proposal seeking a bylaw to prevent the board from seeing a tally of votes cast on certain executive pay matters. [read post]
4 Nov 2007, 7:03 pm
Celgene Corporation et al. v. [read post]
13 Jan 2009, 2:25 pm
A Correspondence item published in the January 1, 2009 edition of the Journal of Clinical Oncology provides some new information about 16 reports of these serious skin rash conditions among patients who used Revlimid from December 2005 -- when this drug was first marketed by Celgene Corporation -- through June 2008. [read post]